Neovacs to proceed with Phase IIb/III trials of TNF-Kinoid in Crohn's and RA
This article was originally published in Scrip
Executive Summary
Neovacs said it expects to begin Phase IIb/III studies of its TNF-Kinoid product candidate in Crohn’s disease and rheumatoid arthritis (RA) next year - a bold move given that Phase II results for the drug in the former indication have not been altogether favourable.